Notice of NHLBI Participation in PAR-22-105 "Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)"
Notice Number:
NOT-HL-22-026

Key Dates

Release Date:

July 18, 2022

Related Announcements

PAR-22-105 - Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Heart, Lung, and Blood Institute (NHLBI) is participating, effective immediately, in PAR-22-105 "Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)".

Applications for studies (clinical trial optional) relevant only to a particular disease or organ system should be directed to the appropriate Division or Center at NHLBI. The Divisions of Cardiovascular Science, Lung Diseases, Blood Diseases and Resources, and the Center for Translational Research and Implementation Science all accept applications to this FOA. NHLBI encourages potential applicants to contact program staff for assistance early in the application process, particularly if you need assistance in identifying where to direct your application. Applications proposing clinical trials may require additional information at the time of award and additional NHLBI oversight.

The following sections of PAR-22-105 have been updated (in bold italics) to reflect NHLBI participation in this Funding Opportunity Announcement.

Part 1. Overview Information

Components of Participating Organizations

National Cancer Institute (NCI)

National Human Genome Research Institute (NHGRI)

National Institute on Aging (NIA)

National Institute on Alcohol Abuse and Alcoholism (NIAAA)

National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

National Institute on Deafness and Other Communication Disorders (NIDCD)

National Institute of Dental and Craniofacial Research (NIDCR)

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

National Institute on Drug Abuse (NIDA)

National Institute of Environmental Health Sciences (NIEHS)

National Institute of Mental Health (NIMH)

National Institute of Neurological Disorders and Stroke (NINDS)

National Institute of Nursing Research (NINR)

National Institute on Minority Health and Health Disparities (NIMHD)

National Center for Complementary and Integrative Health (NCCIH)

National Heart, Lung, and Blood Institute (NHLBI)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Division of Program Coordination, Planning and Strategic Initiatives, Office of Disease Prevention (ODP)

Office of Behavioral and Social Sciences Research (OBSSR)

Office of Research on Women's Health (ORWH)

Catalog of Federal Domestic Assistance (CFDA) Number(s) 93.399, 93.242, 93.172, 93.113, 93.279, 93.846, 93.121, 93.361, 93.213, 93.855, 93.866, 93.173, 93.865, 93.307, 93.853, 93.313, 93.273, 93.847, 93.837, 93.838, 93.839, 93.840, 93.233

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)
Dave Clark, DrPH
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-402-2486
Email: Dave.Clark@nih.gov

Grants Management Contact(s)
Anthony Agresti
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-827-8014
Email: agrestia@nhlbi.nih.gov

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries regarding this Notice to:

Dave Clark, DrPH
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-402-2486
Email: Dave.Clark@nih.gov